Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Handling Cold Chain Breaches During Sample Storage – V 2.0

Posted on By

BA-BE Studies: SOP for Handling Cold Chain Breaches During Sample Storage – V 2.0

Standard Operating Procedure for Handling Cold Chain Breaches During Sample Storage in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/112/2025
Supersedes SOP/BA-BE/112/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for identifying, documenting, investigating, and mitigating cold chain breaches during the storage of clinical samples in Bioavailability/Bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all clinical and laboratory personnel involved in handling, storing, and monitoring biological samples (e.g., plasma, serum) under cold chain conditions (-20°C, -70°C) in BA/BE studies.

3. Responsibilities

  • Sample Storage Technician: Monitors and logs storage temperatures; notifies deviations immediately.
  • QA Officer: Investigates breach events and reviews CAPA implementation.
  • PI/Study Manager: Evaluates sample usability and decides on repeat sampling or exclusions.
  • IT/Engineering: Maintains monitoring systems and calibrates temperature devices.

4. Accountability

The Head of Laboratory Operations is accountable for ensuring uninterrupted cold chain management and responding promptly to any breach to prevent data loss or regulatory non-compliance.

See also  BA-BE Studies: SOP for Preparing Clinical Investigator’s Brochure (CIB) - V 2.0

5. Procedure

5.1 Cold Chain Infrastructure and Monitoring

  1. Ensure all sample freezers are:
    • Maintained at specified temperatures: -20°C or -70°C
    • Fitted with calibrated digital temperature monitors
    • Connected to 24/7 temperature alarm systems
  2. Log temperatures at least twice daily in Annexure-1: Cold Chain Temperature Log.

5.2 Identification of Breach

  1. Breach is defined as any temperature excursion beyond:
    • -20°C ± 5°C for medium-term storage
    • -70°C ± 10°C for long-term storage
  2. Upon breach detection (via logger or manual check), immediately inform QA and PI.

5.3 Initial Response

  1. Label affected freezer “DO NOT USE”.
  2. Relocate samples to backup storage unit within 15 minutes, if conditions are unsafe.
  3. Document relocation and status in Annexure-2: Cold Chain Breach Report.

5.4 Investigation and Documentation

  1. QA initiates a deviation investigation within 24 hours.
  2. Root cause analysis to be conducted using Annexure-3: Temperature Excursion Investigation Form.
  3. Assess sample integrity based on:
    • Type of analyte
    • Duration and temperature of exposure
    • Stability data (refer to protocol or analytical validation report)
See also  BA-BE Studies: SOP for Administration of Study Drug in Fed State - V 2.0

5.5 Corrective and Preventive Action (CAPA)

  1. Develop CAPA in coordination with QA and Facility teams.
  2. Implement engineering controls, retraining, or backup validation based on root cause.
  3. Document CAPA in Annexure-4: Breach CAPA Register.

5.6 Sample Disposition and Reporting

  1. PI to determine usability:
    • If usable, retain with deviation note
    • If not usable, report as lost sample and update sample reconciliation log
  2. Report to Sponsor, IEC, and Regulatory Authority if breach impacts study outcomes.

5.7 Preventive Monitoring and Maintenance

  1. Calibrate all sensors and loggers quarterly.
  2. Test alarm systems monthly and maintain documentation in Annexure-5: Alarm Function Test Log.
  3. Maintain service records for cold chain equipment.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • QA: Quality Assurance
  • PI: Principal Investigator
  • CAPA: Corrective and Preventive Action
  • IEC: Institutional Ethics Committee

7. Documents

  1. Cold Chain Temperature Log – Annexure-1
  2. Cold Chain Breach Report – Annexure-2
  3. Temperature Excursion Investigation Form – Annexure-3
  4. Breach CAPA Register – Annexure-4
  5. Alarm Function Test Log – Annexure-5

8. References

  • ICH E6(R2) – Good Clinical Practice
  • ICH Q1A(R2) – Stability Testing Guidelines
  • Schedule Y – Drugs and Cosmetics Rules
See also  BA-BE Studies: SOP for Room Temperature Monitoring in Sample Collection Areas - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Cold Chain Temperature Log

Date Time Freezer ID Temperature (°C) Logged By
17/04/2025 10:00 AM FZ-20A -21.3 Rajesh Kumar

Annexure-2: Cold Chain Breach Report

Date/Time Freezer ID Max Temp Duration Samples Affected Reported By
16/04/2025 2:45 AM FZ-20A -12.5°C 90 mins 12 Sunita Reddy

Annexure-3: Temperature Excursion Investigation Form

Cause Identified Root Cause Investigated By Corrective Action
Door ajar Manual error during transfer QA Officer Training scheduled

Annexure-4: Breach CAPA Register

Date Issue CAPA Description Closure Date Approved By
17/04/2025 Temp Breach Retraining and equipment alarm testing 18/04/2025 QA Head

Annexure-5: Alarm Function Test Log

Date Freezer ID Alarm Triggered Response Time Tested By
01/04/2025 FZ-20A Yes 2 mins Ajay Verma

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP Release Cold Chain Compliance QA Head
17/04/2025 2.0 Annexures added, updated deviation handling Regulatory Audit Observation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Archiving Method Development Reports – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version